Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Pagoda Biopharma-B (02565) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Pagoda Biopharma is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Pagoda Biopharma previously announced that all conditions of the placement agreement had been met, with the placement completed on December 22, 2025 [1] - Under the terms of the placement agreement, the joint placement agents sold a total of 5.136 million shares at a price of HKD 58.41 per share to no fewer than six subscribers, representing approximately 1.81% of the enlarged H-shares and about 1.31% of the total shares after the placement [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Weisheng Holdings (03393) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Weisheng Holdings is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - Weisheng Holdings has submitted a proposal for a spin-off to the Hong Kong Stock Exchange in accordance with Listing Rule Guidance No. 15, and the exchange has confirmed that the company can proceed with the proposed spin-off [1] - On January 27, 2026, Weiyuan Energy submitted a listing application form (Form A1) to the Hong Kong Stock Exchange through its exclusive sponsor, seeking to list and trade its shares on the main board of the exchange [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kintor Pharmaceutical-B (02171) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Kintor Pharmaceutical-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Kintor Pharmaceutical-B announced a strategic cooperation agreement on February 12, 2026, through its wholly-owned subsidiary, Shanghai Kexing Diagnostic Technology, with Shanghai Jinguang Enterprise Development, a key platform enterprise in Shanghai's Jinshan District [1] - The total investment for this project will not exceed RMB 370 million, aimed at constructing an advanced CAR-T cell therapy product commercialization production base in Jinshan District, Shanghai [1]

Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase of 65.50% from May to September last year, but has since faced a decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2]. Group 1: Stock Performance - After being removed from the Hong Kong Stock Connect list, Gaoshi Medical's stock price initially rose, achieving a monthly "four consecutive increases" [1]. - The stock price saw a cumulative increase of 65.50% from May to September last year, but began a three-month period of sideways movement starting in mid-September [1]. - Since December 22, the stock has declined nearly 20%, effectively reversing all gains made since the mid-year report [1]. Group 2: Market Dynamics - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for the excluded stocks, with Gaoshi Medical being one of them [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors has only decreased by 3% over the past 10 months, indicating limited selling pressure [2]. - The liquidity of Gaoshi Medical's stock has noticeably decreased post-removal, with monthly trading volumes dropping by 84.39% from February to April last year [4]. Group 3: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but net profit fell by 46.75% to 92.394 million yuan due to factors like currency fluctuations and goodwill impairment [7]. - The company has been attempting to adjust its business structure by increasing the proportion of self-owned products, but the revenue from agency products rebounded to 68.55% in 2024 [8]. - In the first half of 2025, Gaoshi Medical achieved revenues of 653 million yuan, a 1.7% increase year-on-year, with a gross profit margin of 48.3%, reflecting an improvement [9]. Group 4: Future Outlook - Analysts project that Gaoshi Medical's revenues will grow to 1.564 billion, 1.715 billion, and 1.875 billion yuan from 2025 to 2027, with corresponding net profits of 135 million, 180 million, and 214 million yuan [9]. - Following the release of the mid-year report, Gaoshi Medical's stock price surged by 19.31% over two days, indicating positive market sentiment towards its performance [9]. - The current trading volume and price movements suggest that the stock may be nearing a bottom, with potential for recovery as market conditions improve [10].

Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase in the first half of the year, but a subsequent decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2][7]. Group 1: Stock Performance - Gaoshi Medical's stock price rose by 65.50% from May to September last year, despite being removed from the Hong Kong Stock Connect list in March [1]. - Following a peak, the stock entered a three-month period of consolidation before declining after December [1]. - The stock has seen a cumulative decline of nearly 20% since December 22, effectively reversing all gains made since the mid-year report [1]. Group 2: Hong Kong Stock Connect Impact - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for excluded stocks, with Gaoshi Medical being one of the affected companies [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors decreased only slightly from 6.85% to 3.85% over ten months, indicating limited selling pressure [2]. Group 3: Trading Volume and Liquidity - Post-removal, the trading volume of Gaoshi Medical's shares significantly decreased, with a drop of 84.39% in monthly trading volume from February to April compared to the previous period [4]. - By December, the monthly trading volume had further declined to just 97.35 million shares [4]. Group 4: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but a 4.1% decrease in gross profit to 663 million yuan, with net profit down 46.75% to 92.39 million yuan [7]. - The decline in profitability was attributed to factors such as exchange rate fluctuations and the implementation of national procurement policies for artificial crystals, alongside goodwill impairment totaling 23.26 million yuan [7]. Group 5: Business Strategy and Future Outlook - Gaoshi Medical is attempting to adjust its business structure by increasing the proportion of self-owned products, although the revenue share from distribution products increased to 68.55% in 2024 [8]. - The company reported a significant improvement in its financials for the first half of 2025, with revenues of 653 million yuan, a 1.7% increase, and a net profit of 35.9 million yuan, up 33.5% [8]. - Analysts project revenue growth for 2025-2027, with expected revenues of 1.564 billion, 1.715 billion, and 1.875 billion yuan, and net profits of 135 million, 180 million, and 214 million yuan respectively [9].

Core Viewpoint - The Hang Seng Index Company will announce the results of the 2025 Q4 index review on February 13, with changes effective from March 9, impacting liquidity and presenting new investment opportunities for investors [1]. Group 1: Stock Inclusion and Exclusion - Over 40 stocks are predicted to be included in the Hong Kong Stock Connect, while more than 20 stocks may be excluded due to insufficient market capitalization [1][2]. - The market capitalization threshold for inclusion in the Hang Seng Composite Index and Stock Connect is approximately HKD 9.307 billion, while the exclusion threshold is HKD 6.115 billion [2]. - A total of 43 companies meet the criteria for inclusion, with notable candidates including JD Industrial, Innovation Industries, and Dipo Technology [2]. Group 2: Market Dynamics and Structural Changes - The adjustment of Stock Connect targets is a complex system considering market capitalization, liquidity, and market structure, rather than a simple "market cap game" [3]. - Companies listed in both A and H shares can be added to Stock Connect without waiting for periodic adjustments, as seen with Naxin Microelectronics and Nanhua Futures [3]. - The adjustment mechanism includes two major adjustments in March and September, and two minor adjustments in June and December, with key dates for companies to meet criteria being June 30 and December 31 [2]. Group 3: Focus on New Economy and Technology Stocks - The potential inclusion list highlights a strong focus on new economy and technology stocks, including AI-related companies and biotech firms [4]. - The information technology sector leads with 15 potential inclusions, followed closely by the healthcare sector with 14, while traditional financial sectors see minimal additions [4]. - The distribution of potential inclusion stocks indicates a structural shift towards technology-driven industries, enhancing asset allocation options for mainland investors [4]. Group 4: Market Vitality and Attractiveness - The dynamic mechanism of Stock Connect enhances liquidity premiums for related industries and improves the overall representativeness and attractiveness of the Hong Kong market [5]. - Continuous expansion and precise adjustments of Stock Connect deepen the interconnectivity between mainland and Hong Kong capital markets, reinforcing Hong Kong's position as an international financial hub [6]. - The ongoing optimization of Stock Connect targets is expected to attract long-term capital and guide funds towards high-growth sectors, contributing to the structural upgrade of the Hong Kong market [6].

Core Viewpoint - The Hang Seng Index Company announced that it will reveal the results of the Hang Seng Index series review for the fourth quarter of 2025 on February 13, with changes to the constituent stocks effective from March 9 [2] Group 1: Index Review Announcement - The announcement pertains to the upcoming review of the Hang Seng Index series [2] - The review results will be disclosed on February 13, 2025 [2] - Changes to the constituent stocks will take effect on March 9, 2025 [2] Group 2: Eligible Companies - A total of 43 companies meet the inclusion criteria for the Hong Kong Stock Connect [2] - Companies with the highest market capitalization include JD Industrial, Innovation Industries, Dipo Technology, Le Comfort, InnoSilicon, Tudatong, and Woan Robotics [2]

Group 1 - The core announcement from the Hang Seng Index Company states that the results of the fourth quarter review for the Hang Seng Index series will be announced on February 13, 2025, with changes effective from March 9, 2025 [1][9] - Predictions indicate that over 40 stocks will be included in the Hong Kong Stock Connect, while more than 20 stocks may be removed due to insufficient market capitalization [1][9] - The adjustments to the Hong Kong Stock Connect not only affect the liquidity of related stocks but also present new investment opportunities for investors [1][9] Group 2 - A total of 43 companies meet the criteria for inclusion in the Hong Kong Stock Connect, with key players such as JD Industrial, Innovation Industry, and Dipo Technology leading in average market capitalization [3][11] - The market capitalization threshold for inclusion in the Hang Seng Composite Index and Hong Kong Stock Connect is approximately HKD 93.07 billion, while the threshold for removal is HKD 61.15 billion [3][11] - The adjustment mechanism for the Hong Kong Stock Connect operates on a quarterly basis, with two major adjustments in March and September, and two minor adjustments in June and December [3][11] Group 3 - The potential inclusion list highlights a strong focus on new economy and technology stocks, with significant representation from the information technology and healthcare sectors [5][14] - The information technology sector leads with 15 potential inclusions, followed closely by healthcare with 14, while traditional financial sectors see only 4 new potential stocks [5][14] - The dynamic adjustment mechanism of the Hong Kong Stock Connect is facilitating a structural shift towards new economy and technology-driven industries, enhancing asset allocation options for mainland investors [5][14] Group 4 - The ongoing expansion and precise adjustments of the Hong Kong Stock Connect are enhancing the overall representativeness and investment appeal of the Hong Kong market [6][15] - The adjustments are expected to attract long-term capital and improve asset quality, promoting deeper linkage between Hong Kong and A-share markets [6][15] - Predictions for the Hong Kong market in 2026 suggest a potential upward trend driven by global liquidity easing, continuous inflow of southbound funds, and the expansion of quality stock options [6][15]

Core Insights - The adjustment of Hong Kong Stock Connect (港股通) for the first batch of 2026 has been finalized, indicating a structural change in the Hong Kong stock market, with southbound funds playing a significant role in influencing stock liquidity and valuations [1] Group 1: Inclusion and Exclusion Criteria - The current inclusion threshold for Hong Kong Stock Connect has risen to 9.317 billion, while the exclusion threshold stands at 6.05 billion [2] - A total of 44 companies meet the inclusion criteria, while 24 companies face the risk of exclusion due to insufficient market capitalization [2][7] - Market capitalization and liquidity are the core indicators determining inclusion or exclusion [2] Group 2: Companies Meeting Inclusion Criteria - Among the 44 companies eligible for inclusion, the average market capitalization is 14.377 billion, with a median of 12.613 billion, indicating overall high quality [2] - The types of inclusion include 40 companies for standard inclusion, 2 for A+H inclusion, and 2 for dual-class share inclusion [2] Group 3: Companies Facing Exclusion Risk - The 24 companies at risk of exclusion have an average market capitalization of only 5.094 billion, all below the 6.05 billion threshold [7] - Notable companies facing exclusion include Youbao Online and Haotian International Construction [7] Group 4: Market Dynamics and Adjustment Mechanism - The adjustment of Hong Kong Stock Connect is based on a complex system that considers market capitalization, liquidity, and market structure [7] - The market capitalization threshold is dynamically adjusted based on the market capitalization distribution of the Hang Seng Composite Index [8] - The liquidity requirement is assessed through the trading volume turnover ratio, which varies based on the listing duration of the companies [10] Group 5: Adjustment Frequency and Fast Inclusion Mechanism - Adjustments to Hong Kong Stock Connect occur four times a year, with two major adjustments in March and September, and two minor adjustments in June and December [11] - New stocks can be included through a fast-track mechanism, with specific criteria for quarterly and special fast inclusion [12]

Group 1 - The Hong Kong Stock Connect securities list will be adjusted, with the addition of Wan Guo Gold Group, effective from December 9, 2025 [1]